Eupraxia Pharmaceuticals Quote - EPRX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

4.91

Bid

4.73

Ask

4.92

Volume

16,571

4.70 Day's Range 4.89

3.07 52 Week Range 7.64

Market Cap

133.955M

Previous Close

4.73

Open

4.72

Last Trade

100

4.91

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

33,410

Shares Outstanding

27,282,000

Dividend Yield

PE Ratio

-4.73

Earnings Per Share (EPS)

-1.03

Revenue

Net Profit

-28.22M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.eupraxiapharma.com

Headquarters

Victoria, British Columbia, Can

Founded

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was $4.73. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of $ 3.07 to $ 7.64.

Eupraxia Pharmaceuticals currently has 27,282,000 shares outstanding. The market capitalization of Eupraxia Pharmaceuticals is $129.04 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.73.

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months Canada NewsWire VICTORIA, BC, Nov. 20, 2024...

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting Canada NewsWire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /CNW/ - Eupraxia...

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire VICTORIA, BC, Nov. 12, 2024...

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.62	14.4522144522	4.29	5.45	4.1	49519	4.84420006	CS
4	1.49	43.567251462	3.42	5.45	3.3	61747	4.31255931	CS
12	1.36	38.3098591549	3.55	5.45	3.07	33410	4.01550099	CS
26	0.9	22.4438902743	4.01	5.45	3.07	23674	3.87800736	CS
52	-0.9	-15.4905335628	5.81	7.64	3.07	32766	4.35582252	CS
156	2.81	133.80952381	2.1	9.1	0.8	27658	4.23628044	CS
260	-2.84	-36.6451612903	7.75	9.1	0.8	25245	4.22560428	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AABAberdeen International Inc	$ 0.065 (18.18%)	226.54k
MDPMedexus Pharmaceuticals Inc	$ 2.45 (15.02%)	46.31k
NCFNorthcliff Resources Ltd	$ 0.04 (14.29%)	5k
SAMStarcore International Mines Ltd	$ 0.16 (14.29%)	200k
GECGlobal Education Communities Corp	$ 0.225 (12.50%)	60k
BNGBengal Energy Ltd	$ 0.005 (-50.00%)	20k
RTGRTG Mining Inc	$ 0.03 (-25.00%)	13k
SMCSulliden Mining Capital Inc	$ 0.015 (-25.00%)	200k
APSAptose Biosciences Inc	$ 0.27 (-20.59%)	346.55k
FLNTFlint Corporation	$ 0.025 (-16.67%)	28k
SUSuncor Energy Inc	$ 58.04 (0.94%)	14.14M
MFCManulife Financial Corporation	$ 45.42 (-0.53%)	9.73M
SLFSun Life Financial Inc	$ 85.54 (-0.23%)	6.19M
BITFBitfarms Ltd	$ 2.96 (3.14%)	6.17M
CNQCanadian Natural Resources Ltd	$ 48.70 (0.83%)	4.91M